Simulations Plus and Three Pharma Companies Collaborate on AI-Driven Drug Development

Why It Matters

Embedding AI directly into validated MIDD workflows accelerates drug discovery while ensuring regulatory‑ready transparency, giving pharma firms a competitive edge in speed and cost efficiency.

Key Takeaways

• AI agents embedded in MIDD workflows across three pharma partners
• Integration uses Simulations Plus platforms: ADMET Predictor, GastroPlus, Thales, MonolixSuite
• Natural-language interfaces automate data processing and multi‑engine simulations
• Partnerships define governance, deployment standards for enterprise AI adoption
• Focus on transparency, reproducibility, and scalable drug development models

Pulse Analysis

Artificial intelligence is reshaping pharmaceutical R&D, but its true impact hinges on seamless integration with existing scientific workflows. Simulations Plus leverages its suite of validated modelling tools—ADMET Predictor for absorption, distribution, metabolism, excretion predictions; GastroPlus for physiologically based pharmacokinetic simulations; Thales for mechanistic disease modelling; and MonolixSuite for population pharmacokinetic analysis—to embed AI agents directly into MIDD pipelines. This approach moves AI beyond isolated analytics, allowing researchers to query models in natural language, automate data curation, and orchestrate complex simulations across multiple engines, thereby shortening iteration cycles and reducing manual error.

The partnership model adopted with three leading pharma companies emphasizes enterprise‑level deployment, governance, and reproducibility. By collaborating with IT departments, Simulations Plus helps define standardized AI integration frameworks that address data security, model versioning, and auditability—critical factors for regulatory compliance. Shared standards for transparency ensure that AI‑generated insights can be traced back to source data and underlying assumptions, fostering trust among scientists, regulators, and investors.

For the broader industry, these collaborations signal a shift toward scalable, AI‑enabled drug development platforms that can be commercialized across therapeutic areas. As AI agents become embedded in day‑to‑day workflows, pharmaceutical firms can expect faster candidate selection, more accurate safety profiling, and ultimately lower development costs. The strategic alignment of AI with proven modelling engines positions Simulations Plus as a pivotal enabler of the next generation of efficient, data‑driven drug pipelines.